UB research may offer a more streamlined approach to developing cancer drugs

Drug discovery can be a frustrating process of trial and error.

Adherence Matters for CVD Secondary Prevention in CPAP Users

Good treatment adherence made a case for the controversial idea of continuous positive airway pressure (CPAP) as secondary cardiovascular disease prevention for people with obstructive

October 6, 2023

Mainz Biomed Announces Collaboration with Fugene Genetics in Israel – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Miscellaneous 18.07.2023 / 09:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed

July 19, 2023

LY-3885125 by Eli Lilly and Co for Non Alcoholic Fatty Liver Disease (NAFLD): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes

September 14, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.